Ipca Laboratories Limited

NSEI:IPCALAB Stock Report

Market Cap: ₹361.5b

Ipca Laboratories Valuation

Is IPCALAB undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of IPCALAB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
₹493.65
Fair Value
188.6% overvalued intrinsic discount
20
Number of Analysts

Below Fair Value: IPCALAB (₹1424.8) is trading above our estimate of fair value (₹493.65)

Significantly Below Fair Value: IPCALAB is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for IPCALAB?

Key metric: As IPCALAB is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for IPCALAB. This is calculated by dividing IPCALAB's market cap by their current earnings.
What is IPCALAB's PE Ratio?
PE Ratio49x
Earnings₹7.38b
Market Cap₹361.48b

Price to Earnings Ratio vs Peers

How does IPCALAB's PE Ratio compare to its peers?

The above table shows the PE ratio for IPCALAB vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average37.6x
AJANTPHARM Ajanta Pharma
34.1x13.32%₹313.6b
GLAND Gland Pharma
37.5x22.28%₹261.7b
506943 J. B. Chemicals & Pharmaceuticals
39.7x17.06%₹261.9b
GLENMARK Glenmark Pharmaceuticals
39.3x28.57%₹411.2b
IPCALAB Ipca Laboratories
49x27.26%₹361.5b

Price-To-Earnings vs Peers: IPCALAB is expensive based on its Price-To-Earnings Ratio (49x) compared to the peer average (37.6x).

Price to Earnings Ratio vs Industry

How does IPCALAB's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
INDSWFTLAB Ind-Swift Laboratories
1.4xn/aUS$56.07m
524652 Ind-Swift
1.3xn/aUS$9.94m
No more companies available in this PE range
IPCALAB 49.0xIndustry Avg. 32.0xNo. of Companies19PE020406080100+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: IPCALAB is expensive based on its Price-To-Earnings Ratio (49x) compared to the Indian Pharmaceuticals industry average (32x).

Price to Earnings Ratio vs Fair Ratio

What is IPCALAB's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

IPCALAB PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio49x
Fair PE Ratio42.3x

Price-To-Earnings vs Fair Ratio: IPCALAB is expensive based on its Price-To-Earnings Ratio (49x) compared to the estimated Fair Price-To-Earnings Ratio (42.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst IPCALAB forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current₹1,424.80
₹1,579.90
+10.89%
16.43%₹1,918.00₹900.00n/a20
May ’26₹1,401.20
₹1,608.57
+14.80%
16.26%₹1,918.00₹900.00n/a21
Apr ’26₹1,390.85
₹1,621.43
+16.58%
16.20%₹1,940.00₹900.00n/a21
Mar ’26₹1,355.35
₹1,621.43
+19.63%
16.20%₹1,940.00₹900.00n/a21
Feb ’26₹1,417.35
₹1,591.05
+12.26%
19.05%₹1,970.00₹900.00n/a20
Jan ’26₹1,692.95
₹1,584.55
-6.40%
19.34%₹1,980.00₹900.00n/a20
Dec ’25₹1,542.55
₹1,551.28
+0.57%
19.60%₹1,930.00₹900.00n/a18
Nov ’25₹1,607.10
₹1,425.47
-11.30%
18.90%₹1,950.00₹900.00n/a17
Oct ’25₹1,491.40
₹1,354.89
-9.15%
16.10%₹1,750.00₹900.00n/a18
Sep ’25₹1,384.65
₹1,319.78
-4.69%
14.74%₹1,600.00₹900.00n/a18
Aug ’25₹1,304.80
₹1,215.50
-6.84%
14.36%₹1,438.00₹900.00n/a18
Jul ’25₹1,135.25
₹1,196.94
+5.43%
16.88%₹1,438.00₹687.00n/a18
Jun ’25₹1,152.15
₹1,206.11
+4.68%
17.56%₹1,505.00₹687.00₹1,424.8018
May ’25₹1,339.50
₹1,163.11
-13.17%
18.46%₹1,505.00₹687.00₹1,401.2018
Apr ’25₹1,241.05
₹1,151.11
-7.25%
14.89%₹1,350.00₹850.00₹1,390.8518
Mar ’25₹1,193.05
₹1,139.44
-4.49%
14.53%₹1,350.00₹850.00₹1,355.3518
Feb ’25₹1,114.45
₹1,005.61
-9.77%
15.96%₹1,200.00₹670.00₹1,417.3518
Jan ’25₹1,119.35
₹992.83
-11.30%
15.00%₹1,200.00₹670.00₹1,692.9518
Dec ’24₹1,149.70
₹987.00
-14.15%
15.34%₹1,200.00₹670.00₹1,542.5518
Nov ’24₹978.75
₹899.72
-8.07%
13.93%₹1,200.00₹670.00₹1,607.1018
Oct ’24₹935.65
₹858.89
-8.20%
10.02%₹1,029.00₹670.00₹1,491.4019
Sep ’24₹866.80
₹859.20
-0.88%
9.77%₹1,029.00₹670.00₹1,384.6520
Aug ’24₹902.40
₹826.47
-8.41%
10.26%₹1,010.00₹670.00₹1,304.8019
Jul ’24₹742.85
₹831.56
+11.94%
10.53%₹1,010.00₹670.00₹1,135.2518
Jun ’24₹705.50
₹848.80
+20.31%
12.57%₹1,096.00₹670.00₹1,152.1520
AnalystConsensusTarget
Consensus Narrative from 20 Analysts
₹1.58k
Fair Value
9.8% undervalued intrinsic discount
20
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/31 08:54
End of Day Share Price 2025/05/30 00:00
Earnings2025/03/31
Annual Earnings2025/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Ipca Laboratories Limited is covered by 46 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Aditya KhemkaAmbit Capital
null nullAnand Rathi Shares and Stock Brokers Limited
Sanjeev ChiniwarAnand Rathi Shares and Stock Brokers Limited